PETRI DISH PERSPECTIVES

Send us Fan MailIn this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients.But over time, it has evolved into something much bigger.We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics.Because 340B isn’t just about drug discounts.It’s about who captures value in the healthcare system and who it’s really meant to serve.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplainedSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026!This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat if cancer treatment wasn’t a drug but a living, evolving system inside your body?In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicineSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology.This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs).At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers.We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs).From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer.If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008.We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind the "Little Blue Box," and the strategic brilliance of the Genomic Health merger. We explore how Kevin Conroy turned a struggling Madison startup into a global diagnostic standard by mastering the one thing most biotechs ignore: the clinical workflow.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives #ExactSciences #AbbottLaboratories #BiotechStrategy #Oncology #Cologuard #LiquidBiopsy #PharmaNews #MAndA #CancerDetection #ScientificTranslator #Diagnostics #HealthTech #KevinConroy #BiotechPodcastSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology.We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massive infrastructure bets currently being made by Big Pharma giants. From the rise of autonomous, "closed-loop" labs to significant improvements in target discovery and preclinical timelines, we analyze where the technology is delivering measurable wins and where the "dirty data" gap still holds the industry back.Finally, we address the hard truths of this transition, including the recent wave of industry layoffs and the emergence of the "Scientific Translator" as the most vital role in the modern lab. We look ahead to a 2030 landscape defined by digital control arms and personalized medicine, offering essential lessons for any professional navigating the risks and rewards of an AI-integrated pipeline.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026!This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.”We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value through cell programming, automation, and massive biological datasets. We also examine the company’s rapid rise, its high-profile SPAC debut, and the intense scrutiny that followed.Along the way, we dive into the science behind synthetic biology, the challenges of scaling engineered organisms, and the big question: can biology truly become an engineering discipline?If you want to understand the future of programmable biology and whether Ginkgo’s platform-first approach can reshape entire industries, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #SyntheticBiology #GinkgoBioworks #Biotechnology #Bioengineering #DrugDevelopment #LifeSciences #Bioeconomy #Startup #SPAC #Innovation #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFrom a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech.In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We explore Sun Pharma’s early focus on underserved therapeutic areas, its aggressive strategy of acquiring distressed assets, and the pivotal deals that expanded its global footprint, from U.S. market entry to the landmark Ranbaxy acquisition.But this story isn’t just about scale. We also dive into Sun Pharma’s evolution beyond traditional generics into high-margin specialty drugs, including biologics, dermatology treatments, and complex formulations and what that shift means for the future of the company.Along the way, we examine the challenges that shaped Sun’s trajectory, including FDA scrutiny, manufacturing setbacks, and the broader pressures of competing in a race-to-the-bottom generics market.If you want to understand how a company can build a global pharma empire without a single blockbuster discovery and why the future of generics is far more complex than it seems, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #Pharma #SunPharma #Generics #DrugDevelopment #Biotechnology #Healthcare #LifeSciences #SpecialtyPharma #BusinessStrategy #EmergingMarkets #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and diabetes while operating outside the pressures of the public stock market.But the fortress eventually cracked.The company became embroiled in one of the most devastating medical scandals in European history surrounding the drug Mediator (benfluorex). After being marketed for decades as a diabetes treatment, the drug was linked to severe heart valve damage and pulmonary hypertension, triggering a national crisis in France and a landmark trial that reshaped pharmaceutical oversight.Yet Servier’s story does not end with scandal.In the past decade, the company has undergone a dramatic transformation, pivoting billions of euros into oncology research and acquiring cutting-edge therapies targeting rare cancers. From precision leukemia drugs like Tibsovo to the breakthrough brain-tumor therapy Voranigo, Servier is rebuilding itself as a major force in targeted cancer medicine.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailMost biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world.In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major therapies, and how its team translated academic discoveries into real treatments for patients with conditions that once had no options.We also dive into the discovery and development stories behind BioMarin’s key drugs, from enzyme replacement therapies that defined the early rare-disease model to newer innovations targeting genetic signaling pathways and gene therapy. Along the way, we examine the strategy that allowed BioMarin to build a sustainable biotech business in markets most pharma companies once ignored.If you want to understand how rare disease innovation works and why this niche has become one of the most important sectors in biotech, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026!This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailBefore the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything.In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a platform many investors didn’t fully understand, and the pivotal partnership with Pfizer that helped deliver one of the fastest vaccine developments in history.But the story doesn’t stop with COVID. We also examine the criticisms, the people behind the company’s rise, and the next frontier BioNTech is chasing — personalized cancer vaccines and the future of programmable medicine.If you want to understand how a biotech platform can reshape global health and what comes after a once-in-a-generation breakthrough, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #BioNTech #mRNA #Biotechnology #Pharma #DrugDevelopment #COVID19 #Vaccines #BiotechPodcast #LifeSciences #HealthcareInnovation #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno, Editas Medicine, Beam Therapeutics, and rising metabolic players like Metsera, ARCH has consistently invested at the frontier, long before the science was commercially proven.We explore how ARCH’s concentrated, high-conviction model differs from traditional venture capital, why it prioritizes platform biology over single assets, and how patience, scientific depth, and risk tolerance have allowed the firm to shape entire therapeutic categories. If you want to understand the invisible capital forces behind CRISPR, mRNA, cell therapy, and the obesity drug boom, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #VentureCapital #ARCHVenturePartners #Biopharma #DrugDevelopment #CRISPR #mRNA #SyntheticBiology #HealthcareInnovation #StartupEcosystem #LifeSciences #MetabolicHealth #GeneEditing #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine.We unpack the scientific and business journey behind blockbuster therapies like Abilify, examine how Otsuka balanced pharmaceuticals with nutrition and consumer health, and dive into the company’s unique culture of long-term thinking and unconventional innovation. We also explore how Otsuka expanded globally, navigated patent cliffs, embraced partnerships, and positioned itself for the future through digital therapeutics and precision medicine.If you’re interested in how companies succeed by thinking differently and what Otsuka teaches us about patience, diversification, and patient-centered innovation; this is an episode you won’t want to miss.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #Pharma #Otsuka #DrugDevelopment #HealthcareInnovation #Biopharma #LifeSciences #PharmaceuticalIndustry #MentalHealthInnovation #DigitalTherapeutics #GlobalPharma #PrecisionMedicine #PetriDishPerspectives #BiotechPodcastSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat if medicine could fix disease at its source… by rewriting the genetic code itself?In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage.We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases.If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026!This month was dominated by a surge in Eli Lilly's deals, partnerships, etc. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away?In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persistence, philosophy, and scientific conviction.We break down how Eisai partnered with Biogen, why leadership under Haruo Naito stayed the course when others exited neuroscience, and how a Japan-based company became a global force in CNS drug development. Along the way, we examine Eisai’s approach to risk, regulation, M&A, and what its future looks like beyond Alzheimer’s.This is a story about long-term thinking in a short-term industry and what happens when belief outlasts doubt.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin #Eisai #Biotech #Pharma #Alzheimers #Neuroscience #DrugDevelopment #Biogen #HealthcareInnovation #PharmaHistory #LifeSciences #BiotechPodcast #ScienceAndBusiness #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFlagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship redefined what it means to create companies from first principles.We unpack how Flagship pioneered the venture creation model, its early proximity to the MIT and Harvard ecosystem, and how relationships with the Langer lab helped give rise to Moderna long before mRNA was mainstream. We also examine how Flagship systematically identified entire sectors, from AI-driven protein design to microbiome therapeutics and sustainable agriculture, and why its biggest bets often looked unreasonable for years before paying off.Finally, we look at the people who made their mark, the lessons Flagship teaches about patience and risk in biotech, and what’s next as the firm pushes into AI-native biology and programmable medicine. If you want to understand how the future of life sciences is designed, not discovered, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#FlagshipPioneering #Biotech #VentureCreation #Moderna #NoubarAfeyan #LifeSciences #Biotechnology #StartupStories #DeepTech #HealthcareInnovation #BioEngineering #AIinBiotech #ScienceToScaleSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailBiogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it.In this episode, we trace Biogen’s full journey, from its academic origins and the rise of interferon therapies for multiple sclerosis, to blockbuster drugs like Avonex and Tysabri. We explore the diseases Biogen chose to fight, why the company doubled down on neurology, and how its scientific culture shaped both its breakthroughs and its blind spots.We then examine Biogen’s high-stakes pivot into Alzheimer’s disease, the controversy surrounding Aduhelm, and the cautious redemption attempt with Leqembi. Along the way, we highlight the people who built Biogen, the alumni who went on to shape the biotech industry, and the hard lessons learned when science, regulation, and patient hope collide.This is a story about ambition, uncertainty, and what it really takes to develop medicines when the biology refuses to cooperate.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biogen #Biotech #Pharma #Neuroscience #Alzheimers #MultipleSclerosis #DrugDevelopment #LifeSciences #Biopharma #HealthcareInnovation #SciencePodcast #BusinessOfBiotech #MedicalResearch #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailTheranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history. In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mythology allowed unproven science to scale into a $9 billion company, how powerful board members and investors failed to ask the right questions, and how whistleblowers and investigative journalism ultimately exposed the truth. This is a story about innovation without evidence, the dangers of charisma over data, and why medicine is uniquely unforgiving of hype. A cautionary tale at the intersection of biotech, venture capital, media, and power.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Theranos #ElizabethHolmes #Biotech #HealthcareInnovation #SiliconValley #MedicalFraud #InvestigativeJournalism #WallStreetJournal #JohnCarreyrou #VentureCapital #HealthTech #ScienceVsHype #BusinessPodcast #BiotechPodcast #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailNovo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness.In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company mastered insulin manufacturing, pioneered drug delivery systems, and quietly built one of the most disciplined scientific cultures in pharma.This is a story about patience, focus, and how decades of unglamorous excellence can suddenly change the world.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#NovoNordisk #Biotech #Pharma #GLP1 #Ozempic #Wegovy #Diabetes #Obesity #Healthcare #LifeSciences #Biopharma #SciencePodcast #BusinessOfBiotech #MedicalInnovation #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025!This month was dominated by a surge in M&A activity and licensing deals.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailBefore there were blockbuster drugs, clinical trials, and biotech startups, there was… dye.In this episode of Petri Dish Perspectives, we explore one of the most overlooked origin stories in modern medicine: how 19th-century chemical dye companies laid the foundation for today’s pharmaceutical giants. From coal tar chemistry and synthetic pigments to the birth of industrial drug discovery, this episode unpacks why companies like Bayer, BASF, Ciba, and Hoechst evolved from coloring textiles to curing disease.We dive into the science that connects dyes and drugs, the role of wartime chemistry and national strategy, and the researchers who transformed color into cure. This is the story of how industrial chemistry reshaped medicine and why modern pharma still carries the DNA of its dye-making past.Whether you’re in biotech, pharma, or just curious about how science and history collide, this episode reveals why the pharmaceutical industry didn’t start in hospitals but in chemistry labs.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #PharmaHistory #DrugDiscovery #IndustrialChemistry #Biotechnology #Pharmaceuticals #SciencePodcast #ChemistryToCures #MedicalInnovation #BiotechEducationSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global collaboration. We unpack how Astellas quietly repositioned itself toward oncology, gene therapy, and regenerative medicine while navigating the challenges of globalization, risk-taking, and long development timelines.This episode is about how long-term thinking, scientific rigor, and cultural continuity can still win in an industry driven by speed.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Astellas #Biotech #Pharma #DrugDiscovery #Oncology #PrecisionMedicine #JapanesePharma #Xtandi #TransplantMedicine #Biopharma #LifeSciences #PharmaStrategy #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention.We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’ll learn how visionary leaders, bold pipeline bets, and a focus on precision medicine shaped Novartis into a global powerhouse.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Novartis #BiotechPodcast #DrugDiscovery #Gleevec #CAR_T #GeneTherapy #OncologyInnovation #PharmaStrategy #PetriDishPerspectives #HealthcareInnovation #PrecisionMedicine #LifeSciences #BiotechResearchSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailCan a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation.In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS, a closed-loop platform that generates massive, proprietary biological data. Learn about the company's bold vision, from the crucial $50 million NVIDIA investment and the strategic merger with Exscientia to the immense computational power of the Boltz-2 supercomputer. We analyze their pipeline progress in oncology and rare diseases, discuss the challenges of high cash burn (like the recent pipeline streamlining in November 2025), and examine their critical partnerships with giants like Roche/Genentech. Discover why Recursion is leading the charge to build the digital "Map of Biology and Chemistry" to cut drug discovery time from a decade to mere years.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Recursion #TechBio #AIDrugDiscovery #NVIDIA #Biotech #PharmaInnovation #MachineLearning #OmicsData #Genomics #RecursionOS #PetriDishPerspectives #BiotechPodcastSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025!This month was dominated by a surge in M&A activity, with high-profile bidding wars! 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailUnlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell.In this episode, we trace the incredible scientific journey of BsAbs: from the manufacturing failure of the Quadroma Problem to the engineering solution of the "Knobs-into-Holes" strategy and the super-potent BiTE format. You'll hear how drugs like Blinatumomab have become "off-the-shelf" T-cell therapies, transforming treatment for blood cancers. We also explore the challenges of managing side effects like Cytokine Release Syndrome (CRS) and the promise of using BsAbs to conquer solid tumors. If you want to understand the sharp edge of modern cancer research, this is a must-listen.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#BispecificAntibodies #Immunotherapy #CancerResearch #BiotechBreakthrough #Oncology #TCellEngager #SciencePodcast #DrugDiscovery #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk.We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company.If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciencesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we dive into the untold story of Charles River Laboratories, the quiet giant behind nearly every major drug you’ve ever heard of.From its origins on the banks of Massachusetts’ Charles River, where Dr. Henry Foster began breeding lab rats to support post-war research, to its evolution into a global scientific infrastructure company, Charles River has shaped the very foundation of modern drug development.We’ll explore how a small animal breeding business became the unseen force driving pharmaceutical innovation, the company’s expansion under James Foster, and its deep involvement in gene therapy, biologics, and vaccine testing.You’ll also hear about the complex ethical landscape Charles River navigates balancing innovation and regulation in a world demanding both faster cures and higher transparency.By the end of this episode, you’ll understand why behind every breakthrough, from oncology to rare diseases, there’s often a quiet partner ensuring that science moves safely from lab bench to bedside.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhinSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the remarkable story of Regeneron Pharmaceuticals, from its humble beginnings in Tarrytown to becoming one of the world’s leading biotech innovators.Discover how founders Leonard Schleifer and George Yancopoulos turned early failure into scientific triumph with breakthrough drugs like Eylea, Dupixent, and the COVID-19 antibody cocktail that changed the global response.We explore how Regeneron built a culture rooted in pure science, balanced innovation with controversy, and redefined what it means to be a biotech powerhouse in a pharma-dominated world.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechUnleashed #Regeneron #LeonardSchleifer #GeorgeYancopoulos #Eylea #Dupixent #VelocImmune #BiotechPodcast #LifeSciences #PharmaInnovation #DrugDiscovery #COVID19 #HealthcareInnovation #BiotechStorytellingSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat if the cure for cancer or the key to mental health, wasn’t hidden in a new drug, but in data itself? In this episode of Petri Dish Perspectives, we uncover the story of Tempus AI, the company turning raw medical information into lifesaving insight.Founded by Eric Lefkofsky, the entrepreneur behind Groupon, Tempus began as a deeply personal mission to bring clarity to cancer care. Today, it’s one of the most advanced AI-driven healthcare platforms in the world, combining genomics, clinical data, and machine learning to help doctors make better, faster decisions.We explore how Tempus built one of the largest clinico-genomic databases in existence, its bold leap into psychiatry, cardiology, and COVID research, and how it went public to cement its place at the forefront of precision medicine.If you’ve ever wondered how AI is reshaping healthcare from the inside out, this episode is your front-row seat.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechUnleashed #TempusAI #EricLefkofsky #PrecisionMedicine #AIinHealthcare #Genomics #CancerResearch #DigitalHealth #HealthcareInnovation #BiotechPodcast #HealthTech #LifeSciences #DataDrivenMedicine #FutureofHealthcareSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat if the secret engine driving modern drug discovery wasn’t in Boston or Basel, but in Shanghai? In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives deep into the rise of WuXi AppTec, a company that redefined how the world develops medicine.We explore its fascinating journey, from a humble chemistry startup founded by Dr. Ge Li to a global R&D and manufacturing giant that helps nearly every top pharma and biotech company bring therapies to life. You’ll learn how WuXi pioneered the “R&D as a Service” model, bridged East and West in biotech innovation, and powered breakthroughs from cell and gene therapy to AI-driven drug design.We also unpack its controversies, geopolitical challenges, and the lessons it offers about globalization, innovation, and resilience in today’s biotech landscape.If you’ve ever wondered how new drugs move from an idea to reality and who’s quietly making it happen behind the scenes, this episode is for you.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#BiotechUnleashed #PetriDishPerspectives #WuXiAppTec #BiotechPodcast #DrugDiscovery #GlobalBiotech #CRO #PharmaInnovation #LifeSciences #BiotechChina #GeLi #PharmaPartnerships #HealthcareTransformation #MedicalInnovationSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFrom a small pharmacy in Massachusetts to a $100 billion healthcare empire, CVS Health has redefined what it means to be a pharmacy. In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into CVS’s fascinating evolution, from its early days as Consumer Value Store to its bold moves acquiring Aetna and transforming into a fully integrated healthcare provider.We explore how CVS blended retail, insurance, and clinical services to build one of the most powerful healthcare ecosystems in the United States and how it continues to shape the future of accessible care through digital transformation, AI, and pharmacy innovation.We uncover how a simple idea, providing affordable, convenient health access, turned into one of the most ambitious healthcare transformations of our time.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#CVSHealth #PetriDishPerspectives #BiotechUnleashed #HealthcareInnovation #PharmacyEvolution #Aetna #MinuteClinic #HealthTech #DigitalHealth #HealthcareStrategy #Manead #Podcast #BiotechStorytelling #HealthTransformationSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFrom a lizard’s venom to Hollywood’s favorite weight-loss trend, this episode of Petri Dish Perspectives: Biotech Unleashed dives deep into the fascinating journey of GLP-1 agonists. Discover how scientists uncovered a gut hormone that revolutionized diabetes care, led to the creation of Ozempic and Mounjaro, and sparked a cultural movement around body image and health. We’ll trace the science, the breakthroughs, and the billion-dollar race shaping the future of metabolic medicine.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#GLP1 #Ozempic #Mounjaro #Wegovy #BiotechUnleashed #PetriDishPerspectives #Biotech #Pharma #DrugDiscovery #Obesity #Diabetes #MetabolicHealth #HealthcareInnovation #SciencePodcastSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat if you could silence disease at its genetic root? That was the bold promise behind RNA interference (RNAi), one of the most groundbreaking scientific discoveries of the 21st century.In this episode, we dive into the story of Alnylam Pharmaceuticals, from its founding by a powerhouse team of Nobel laureates, pioneering scientists, and biotech visionaries, to its transformation into the world’s first RNAi therapeutics company. We explore the challenges of turning a fragile lab discovery into medicine, the blockbuster drugs that redefined rare disease treatment, and the people who made it all possible.Whether you’re a biotech enthusiast, a student of innovation, or just curious about how cutting-edge science becomes lifesaving therapy, this episode will take you inside the revolution that gave rise to RNAi medicines.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#BiotechUnleashed #Alnylam #RNAi #BiotechPodcast #RareDisease #DrugDiscovery #BiotechHistory #GeneticMedicineSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFrom its humble beginnings in 1781 as a family-run herbal medicine shop in Osaka to becoming one of the world’s top 10 pharmaceutical companies, Takeda’s story is one of resilience, reinvention, and bold transformation.In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead unpacks Takeda’s 240-year journey, from the vision of founder Chobei Takeda, through the blockbuster eras of Prevacid and Actos, to the game-changing acquisition of Shire under CEO Christophe Weber. We’ll dive into the discovery stories behind Takeda’s most important drugs, the leaders who left their mark, and the lessons this Japanese giant offers on balancing tradition with global ambition.Whether you’re fascinated by pharma history, curious about blockbuster drug stories, or want to understand how one company bridged centuries of medicine, this episode has it all.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Takeda #BiotechPodcast #PharmaHistory #DrugDiscovery #HealthcareInnovation #RareDiseases #BiotechUnleashed #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailFrom secrecy and skepticism to one of the fastest vaccine rollouts in history, this episode of Petri Dish Perspectives: Biotech Unleashed dives into the remarkable journey of Moderna. We trace the company’s early hype, billion-dollar partnerships, and criticism for overpromising, through to its historic COVID-19 vaccine that changed global medicine. What’s next for Moderna beyond the pandemic? Tune in to explore how one biotech bet on mRNA and won.Whether you’re a biotech enthusiast, a healthcare professional, or just curious about the companies that quietly keep hospitals running, this episode sheds light on why Moderna deserves your attention.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Moderna #mRNA #BiotechUnleashed #PetriDishPerspectives #COVID19Vaccine #Biotech #Pharma #DrugDevelopment #Innovation #Healthcare #VaccinesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailBaxter may not always grab the biotech headlines, but its impact on modern healthcare is impossible to ignore. From the first commercially prepared IV solutions in the 1930s to pioneering dialysis fluids, blood systems, recombinant hemophilia therapies, and parenteral nutrition, Baxter has consistently solved medicine’s “unsexy but essential” problems.In this episode, we dive into the company’s origins, explore the backstories of its most important innovations, and trace how it spun off biotech powerhouse Baxalta, later snapped up by Shire and Takeda. Along the way, we highlight the people who left their mark and extract key lessons from Baxter’s journey through growth, crisis, and reinvention.Whether you’re a biotech enthusiast, a healthcare professional, or just curious about the companies that quietly keep hospitals running, this episode sheds light on why Baxter deserves your attention.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhinHashtags: #BiotechUnleashed #PetriDishPerspectives #Baxter #BiotechHistory #HealthcareInnovation #Biopharma #LifeSciences #DrugDiscovery #MedicalDevices #PharmaIndustrySupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead explores the remarkable journey of AstraZeneca, from its unlikely Swedish-British merger to blockbuster drugs like Nexium and Crestor, through near-decline, and ultimately its reinvention as a science-driven leader in oncology, cardiometabolic health, and global public health. Discover how bold leadership, high-risk bets, and groundbreaking discoveries like Tagrisso, Enhertu, and Farxiga transformed AstraZeneca into one of today’s most innovative pharmaceutical giants.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#AstraZeneca #BiotechUnleashed #PetriDishPerspectives #BiotechPodcast #PharmaInnovation #Oncology #CardiometabolicHealth #PrecisionMedicine #DrugDiscovery #HealthcareLeadershipSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the remarkable and controversial story of Gilead Sciences, a company that redefined what medicine could achieve. From its beginnings in the late 1980s under physician-scientist Michael Riordan, Gilead transformed antiviral drug development with breakthroughs in HIV treatment, revolutionized global health with a cure for hepatitis C, and pushed into oncology with cutting-edge CAR-T therapies.But alongside these triumphs came firestorms of criticism, from the $84,000 price tag of Sovaldi to debates around HIV drug access and patents. Gilead has long walked the fine line between lifesaving innovation and public outrage, forcing society to wrestle with the question: What is the true price of a cure?Join us as we unpack Gilead’s origins, its blockbuster breakthroughs, its controversies, and what lies ahead for one of biotech’s most influential and polarizing companies.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #GileadSciences #HIV #HepatitisC #CART #Oncology #DrugDiscovery #Pharma #HealthcareInnovation #MedicalBreakthroughs #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the story of GlaxoSmithKline (GSK), one of the world’s most influential pharma giants!From scaling up penicillin production in WWII, to pioneering semi-synthetic antibiotics like amoxicillin, to leading the global vaccine race with Cervarix and Shingrix, GSK has left an indelible mark on modern medicine. We also explore its groundbreaking role in HIV treatment through ViiV Healthcare, and the blockbuster drugs that reshaped respiratory and infectious disease care. Along the way, we draw key lessons on adaptability, collaboration, and the power of prevention in pharma’s evolving landscape.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#GSK #Pharma #Vaccines #BiotechPodcast #DrugDiscovery #HIV #Shingrix #Cervarix #Antibiotics #Asthma #PetriDishPerspectivesSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, we dive deep into the origin story of Amgen, a company that helped turn “biotechnology” from a niche lab concept into a global medical force.We’ll trace Amgen’s unlikely beginnings in 1980, a time when gene splicing was still the stuff of scientific legend and meet the eclectic founding team: George Rathmann, the charismatic chemist-turned-executive; Winston Salser, the UCLA scientist eager to bring basic research to patients; Bill Bowes, the venture capitalist who had already bet big on Genentech; and Ray Schinazi, the young medicinal chemist destined to become an antiviral pioneer.From its scrappy early days in Thousand Oaks to its first blockbuster drugs like Epogen and Neupogen, Amgen’s story is one of scientific daring, boardroom brinkmanship, and relentless pursuit of innovation. We’ll explore the company’s pivotal moments, the personalities who shaped its path, and how it helped define the modern biotech industry.Whether you’re a biotech insider, a science history buff, or just curious about how life-saving drugs make it from idea to reality, this is one you won’t want to miss.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Amgen #BiotechHistory #PharmaInnovation #DrugDiscovery #BiotechPodcast #ScienceStorytelling #Biotechnology #HealthcareInnovation #LifeSciences #PetriDishPerspectives #BiotechUnleashedSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWhat happens when one of the world’s most powerful genomics companies rises from a college dorm in China and goes on to challenge the West’s biotech dominance? In this episode of Petri Dish Perspectives: Biotech Unleashed, we unravel the story of BGI Genomics, a company at the intersection of cutting-edge science, national ambition, and global controversy.From decoding the human genome to building the world’s largest sequencing fleet, BGI’s journey is as bold as it is complex. We’ll explore the vision of its founders, its scientific breakthroughs in synthetic biology and population-scale genomics, its collaborations and tensions with Western partners, and the ethical debates surrounding its work in data privacy and government-backed research.Whether you're in biotech, healthcare, or just fascinated by the future of science, this episode dives into how BGI is reshaping medicine, research, and geopolitics and what we can all learn from its rise.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#BGIGenomics #Genomics #ChinaBiotech #BiotechPodcast #DNASequencing #SyntheticBiology #PetriDishPerspectives #BiotechUnleashed #Bioethics #GlobalHealth #PrecisionMedicine #HumanGenomeProject #BGISupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead takes you inside the remarkable story of Abbott Laboratories: a company that doesn’t chase headlines but touches billions of lives every day.From its origins in 1888 as a small Chicago pharmacy mixing precise plant-based pills, Abbott has grown into a global healthcare powerhouse behind life-changing products like the FreeStyle Libre glucose monitor, BinaxNOW COVID-19 tests, Similac baby formula, Ensure nutrition shakes, and cutting-edge heart devices.You’ll hear how a frontier doctor’s mission for safer, more reliable medicine sparked 135+ years of steady, practical innovation, from mass-producing penicillin in WWII to pioneering rapid diagnostics in a pandemic. You’ll also learn how Abbott’s global workforce and patient-first mindset continue to solve everyday health challenges in ways that quietly shape our world.Grab your coffee, settle in for under 30 minutes, and discover why Abbott proves that sometimes the most powerful biotech breakthroughs aren’t flashy moonshots, they’re the everyday tools that keep us living longer, healthier, and freer lives.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #HealthcareInnovation #Abbott #PetriDishPerspectives #SciencePodcast #MedicalDevices #Diagnostics #GlucoseMonitoring #NutritionScience #HealthTech #LifeSciences #PodcastRecommendationSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailDISCLAIMER: This is a consistently changing situation. The episode was recorded approximately 4 PM EDT Monday, July 21, 2025.  As of 7.40 PM EDT Monday, July 21, 2025 (Source: Sarepta), "Sarepta Therapeutics notified the U.S. FDA of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025."🎙️ When Hope Collides with Risk: Sarepta’s Gene Therapy CrisisIn this episode of Petri Dish Perspectives,  Manead goes off-script to unpack one of the hottest biotech stories in the headlines today: the unraveling of Sarepta Therapeutics.What began in a small Oregon lab in 1980 as Antivirals Inc. evolved into Sarepta, a pioneer in the fight against Duchenne muscular dystrophy (DMD). From early exon-skipping breakthroughs to the dazzling promise of its gene therapy, Elevidys, Sarepta has long been a symbol of hope for families facing an otherwise devastating disease.But in 2025, that hope hit a hard wall: patient deaths, regulatory clashes, and a growing crisis that’s shaking confidence in gene therapy as a whole. In under 30 minutes, Manead breaks down Sarepta’s 40-year journey, the science, the promise, the standoff with the FDA  and what this turning point means for the future of genetic medicine.This isn’t just another biotech update, it’s a raw look at what happens when cutting-edge hope meets the harsh edge of reality.Grab your coffee or tea, hit play, and stay curious.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #GeneTherapy #Sarepta #DMD #FDA #RareDisease #PetriDishPerspectives #BiotechUnleashedSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail🔬✨ From Cystic Fibrosis Breakthroughs to Gene Editing CuresIn this episode of Petri Dish Perspectives: Biotech Unleashed, Manead unpacks how Vertex turned cystic fibrosis from a fatal disease into a treatable condition and why they’re now tackling sickle cell, diabetes, and more with CRISPR and stem cell science.Discover how visionary chemists, Nobel-winning gene editors, and patient advocates built one of biotech’s most inspiring success stories, proving that deep science and real patient impact can go hand in hand.Grab your coffee and hit play! 🚀🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Biotech #VertexPharma #CRISPR #GeneEditing #CysticFibrosis #RareDisease #HealthcareInnovation #PetriDishPerspectives #BiotechPodcastSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail🧬 From VC to Blockbusters: The Genentech Story In Episode 11 of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the legendary rise of Genentech, the startup that sparked the biotech revolution. From its humble beginnings in a borrowed lab to pioneering insulin, tPA, Herceptin, and more, learn how Genentech turned recombinant DNA into real-world cures. Discover the bold VC bets, game-changing antibodies, and the Roche acquisition that preserved its science-first culture. A must-listen for biotech nerds and curious minds alike!🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#Genentech #BiotechPodcast #Herceptin #Avastin #Rituxan #RecombinantDNA #OncologyInnovation #PetriDishPerspectives #HealthcareInnovation #PharmaHistory #RocheGroup #StartupToSuperpowerSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.